The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
Australian Unity Funds Management
Advised Australian Unity Funds Management on a A$320m equity raising and A$80m cash liquidity offer for Australian Unity Healthcare Property Trust
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
Refinancing of syndicated bank debt facilities
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
Moorebank Intermodal Terminal
Acted as independent advisor to the Australian Government in a peer review of the proposed intermodal terminal linking Sydney’s major port with Australia’s road and rail system
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics